Catalonia Life Sciences Report 2011

Transcription

1 Catalonia Life Sciences Report 2011

2 2

3 Contents Chapter 1 Preface 4 Chapter 2 Scope of the report 8 Chapter 3 Introduction to the Catalonia Life Sciences Sector 10 Chapter 4 National and International Benchmarking 30 Chapter 5 R&D in Catalonia 36 Chapter 6 Financing 44 Appendix Selection of Catalonia Research Centers and Large Facilities 53 Appendix Scientific & Technology Parks 54 Glossary of terms 55 3

4 The commitment to innovation should be the best corporate insurance to overcome the crisis Chapter 1 4 Biocat Catalonia Lifesciences

5 Preface Silvia Ondategui-Parra, MD, MPH, MSc, PhD Partner - Mediterranean Life Sciences Leader / Global Market Access Leader An increasingly demanding market In the last years the biotechnology market has been constantly increasing at the expense of traditional chemistry. Additionally, the growth of biotechnology has become the ultimate pillar for international pharmaceutical research to spread. In turn, small biotechs aspiration is for big pharma companies to adopt their molecules as soon as possible, since development is expensive and it is impossible for them to face future on their own. This objective seems more elusive with the crisis: labs do not want to take risks and prefer to wait until success is ensured. Indeed, biotechnology is the great hope and, in figures, around 200 compounds in the late stages of research could generate 150,000 millions a year. But good intentions are not enough, and in this increasingly demanding market an efficient strategy is called for. The present is asking us to be more dynamic, to take new business paths and lean on partners to achieve goals. In Catalonia and at global level, investments in innovation are growing exponentially in order to satisfy ever more informed patients, with growing decision-making power, and a health system which is increasingly focused on improving its management cost. In this regard, the role of the companies in this industry goes far beyond mere development and manufacture of products. This evolution is being prompted by fast developments in information technology, lack of solvency and difficulties in health system sustainability at global level. Opportunities generated in this new scenario are attracting a growing number of new non-traditional players in the healthcare area. At Catalan level, biotechnology is a powerful although industry. On the other hand the pharma industry, which represent one of the most profit-generating industry is well established in Catalonia. That is why synergies between Biotech and pharma companies should be deeply fostered in order to cooperate in joint projects for advancing on biotechnological research and innovation. In order to carry out these developments, Governments and companies should opt for business models that are better managed, more efficient and whose future feasibility is guaranteed. They should not avoid the challenges laying ahead within an ever-changing environment deeply affected by the financial crisis. In conclusion, we are aware that the commitment to innovation should be the best corporate insurance to overcome the crisis. Prospects for the coming years are not good. Traditionally, the pharma industry links its R&D investments to turnover evolution, even under the current scenario where companies turnover is decreasing. Catalonia Life Sciences Report

6 Catalonia has 21% of all the companies of the Spanish biotechnology sector. The total turnover of the sector in the BioRegion totals more than 15,000 Million 6 Preface

7 Montserrat Vendrell CEO, Biocat Accelerating opportunities for the BioRegion of Catalonia Over the past 10 years, Catalonia has seen an unprecedented level of growth in its research capacities, putting it among the most dynamic and productive regions in Europe in terms of knowledge generation. While Catalonia accounts for 1.5 % of Europe s population, it contributes to 1.69 % of its GDP, 2.98 % of scientific production and boasts 3.48 % of ERC grants (2011), two fold the European average, only after Switzerland, Israel, UK and Belgium. Furthermore, joint efforts of both the Catalan and Spanish governments, have allowed for the construction of key scientific facilities such as the National Genome Analysis Center (CNAG), the Alba-CELLS Synchrotron, or the Barcelona Supercomputer Mare Nostrum. Catalonia has 80 bioscience research centers some of which are international benchmarks in genomics (CRG), photonics (ICFO) or oncology (IRB). Alongside this scientific development, the business sector has experienced unstoppable growth since 2000 at a rate of 15% to 30% per year and is now made up of 480 companies, including biotechnology, pharmaceutical, medical technology and sectorservices firms. This business activity is concentrated (85% of the organizations in the sector) mainly around Barcelona, which is also home to most of the 20 science parks in the region. Although the majority of these companies (65%) are SMEs and despite the adverse economic conditions they have had to deal with over the past two years, the comparative analysis Biocat carried out for the 2009 and 2011 fiscal years shows a positive evolution both in economic terms and in research capacities. Catalonia has 21% of all the companies in the Spanish biotechnology sector. The total turnover of the sector in the BioRegion totals more than 15,000 millions, with more than 2,300 millions in capitalization, which more importantly tripled in the time period. The increase in investment 92% of which is private has been accompanied by a significant increase in research capacities in the clinical phases and has allowed these companies to have a pipeline of 270 new therapeutic products and more than 300 new medical technologies. Biocat was created in 2006 by the Catalan Government, the Barcelona City Council, universities, hospitals, research centers and companies to boost a strong BioRegion, competitive at international level. This report sums up the assets this concerted public/private effort has achieved at present, which have made Catalonia a benchmark in clinical innovation and advanced therapies with a number of top-notch projects in the pipeline at our companies and research centers. New diagnostic tools to detect cancer or a predisposition to cardiovascular disease, genetic tests to discover a patient s sensitivity to specific medicines, a new vaccine for tuberculosis and one for malaria in the final clinical phases, new probiotic foods, agrifood pathogen detectors, surgical biomaterials, new biological or nanotechnological methods for drug encapsulation and delivery, new components for the cosmetics industry. These are just some examples of the products Catalan biotechnology firms have already put on the market or are developing at the moment. They are also an example of the sector s potential, which is the result of the ongoing effort Catalonia has made over the past 15 years to drive research and a knowledge-based economy. Naturally, in order to make the most of its potential, Catalonia must collaborate with other clusters such as Massachusetts, Maryland, California and more. We hope this report will be a tool to drive this cooperation in order to fuel a sector that is key to tackling the large-scale challenges currently facing the world while, at the same time, guaranteeing economic growth and social wellbeing. Catalonia Life Sciences Report

8 Executive Summary 2Chapter 2 8 Catalonia Life Sciences Report 2011

9 Scope of the report Catalonia is the region that makes the biggest contribution to the Spanish economy, producing the 18.6% of the country s GDP. Its traditional business dynamism and its entrepreneurship culture, along with the political will of the autonomous government, have allowed the development, during the last ten years, of a strong R&D system and a huge number of innovative companies in knowledgebased sectors as life sciences. Although the negative impact of the global economic crisis on R&D investments, both public and private, the biotechnology industry in Catalonia is still on an upward trend and indicators show positive evolution. The purpose of the Catalan edition of the Life Sciences Report issued by Ernst & Young, in collaboration with Biocat*, is to offer an in-depth analysis of the industry: on one hand, to show the main figures, analyzing the current status of biotechnology, biomedicine and medical technologies in Catalonia, within a global economic instability environment; on the other hand, to see the evolution of the industry in recent years and identify new challenges, strategies and future prospects. In the preparation of this report, we have taken into account the content of Biocat Report 2011, based on data gathered from an extensive survey sent to both public and private entities that perform their work and research activities within biotechnology, biomedicine and medical technology, which together constitute Catalonia s BioRegion. The survey was sent out in December 2010 to 435 research groups and to 450 companies in the BioRegion, 49.5% of which responded. This high level of survey participation (438 organizations) has allowed a consistent analysis of Catalan life sciences companies and research institutions, including some estimates for the sector as a whole. All other consulted sources are explicitly identified where appropriate. Thus, the final objective is to highlight the relevance of the biotechnology, biomedicine and medical technologies in Catalonia that could become the driving force of Catalan economy and innovation, identifying the strengths, pending challenges and the appropriateness of establishing long-term policies. *Biocat is the entity responsible for boosting and fostering the BioRegion in Catalonia. For further information please visit Catalonia Life Sciences Report

10 3Chapter 3 10 Catalonia Life Sciences Report 2011

11 Introduction to the Catalonia Life Sciences Sector With more than 1,100 registered entities, including research institutions and companies, Catalonia is the leading biocluster in Spain and a reference hub in Southern Europe. The steady increase of the number of companies and several initiatives to foster research and innovation prove the BioRegion s dynamism. Figure 3.1 Biotechnology and biomedicine subsectors The entities that constitute Catalonia Life Sciences sector are grouped in one of the major biotechnological clusters in Spain: the BioRegion. The BioRegion is Catalonia s biotechnology, biomedicine and medical technologies cluster. It comprises biotechnology, pharma and medical technology companies, as well as universities, hospitals and research centers. It also includes structures and networks supporting transfer of knowledge and innovation. According to data gathered in the Biocat directory in June 2011 the BioRegion consists of 1,156 entities, which cover strongly interconnected activities (figure 3.1). As shown in figure 3.2, the main group in Biocat directory is integrated by companies (481) and it also includes 80 research centers on life sciences, 15 hospitals and 12 universities. These three types of organizations account for 435 research groups (56.1% in universities, 33% in research centers, and 7.4% in hospitals) that are also registered in the Biocat directory. Green Biotech Green biotechnology deals with the use of environmentally-friendly solutions as an alternative to traditional agriculture, horticulture, and animal breeding processes. An example is the designing of transgenic plants that are modified for improved flavor, for increased resistance to pests and diseases, or for enhanced growth in adverse weather conditions White Biotech White biotechnology, or industrial biotechnology, as it is also known, refers to the use of living cells and/or their enzymes to create industrial products that are more easily degradable, require less energy, create less waste during production and sometimes perform better than products created using traditional chemical processes Red Biotech Red biotechnology refers to the use of organisms for the improvement of medical processes. It includes the designing of organisms to manufacture pharmaceutical products like antibiotics and vaccines, the engineering of genetic cures through genomic manipulation, and its use in forensics through DNA profiling Biomedicine Pharma activites Pharma develops, produces, and markets drugs licensed for use as medications. Pharmaceutical companies are allowed to deal in generic and/or brand medications and medical devices. They are subject to a variety of laws and regulations regarding the patenting, testing and ensuring safety and efficacy and marketing of drugs Medical technology Medical Technology encompasses a wide range of healthcare products and is used to diagnose, monitor or treat diseases or medical conditions affecting humans. Such technologies (applications of medical science) are intended to improve the quality of healthcare delivered through earlier diagnosis, less invasive treatment options and reductions in hospital stays and rehabilitation times. Recent advances in medical technology have also focused on cost reduction Catalonia Life Sciences Report

12 Catalonia s BioRegion is one of the most dynamic bioclusters in Europe Catalonia s BioRegion is one of the more dynamic bioclusters in Europe. It has a majority of young and small start-up between its companies but it has also an increasing capacity of research and manufacturing of innovative products both in the private sector and in public institutions. Catalonia also outstands among other bioregions for the creation of new biotech companies, with a steady increase of 15% per year in 2010 and Other European clusters (figure 3.3) have remained stable in size or are stagnated economically and financially in recent years. Others, such as BioTOP Berlin or Oxford biocluster (OBN), have also shown notable growth in the last two years. Both cases are linked to the traditional dynamism of the industry in these areas and the economic power of both regions. Figure 3.2 Distribution of different types of organizations in the BioRegion (2011) Research groups University Research Center 7% 4% Hospital 33% Other 56% Company 2% 2% 1% 1% 11% 3% 4% 8% 68% Technology infraestructure & Scientific Service Entity of support Scientific - Technologic Park Research Center Hospital University Large infraestructure Technologic center 12 Catalonia Life Sciences Report 2011

13 Figure 3.3 Main European clusters Taking into account the pressure of the economic context and the internal maturation process of BioRegion, it is likely that the set-up of new companies will tend to stabilize, while other indicators related to consolidation stages are expected to increase, i.e. the companies turnover, volume of hired personnel, internationalization or the number of new products launched into the market. Although Chapter 5 offers a comprehensive panorama about R&D in Catalonia it is worth mentioning in this introduction some new initiatives and processes that have reinforced the capacities of the BioRegion both in research and in technology transfer. Uppsala Bio Health research centers In March 2011, Sant Pau Institute of Biomedical Research (IIB Sant Pau) was accredited by Spanish Science Ministry (through the Carlos III Health Institute, ISCIII) as a Health Research Institute. It was the fifth Catalan hospital research center receiving this recognition, that only 16 hospital institutes all over Spain have. IDIBAPS (August Pi i Sunyer Biomedical Research Institute), linked to Hospital Clinic; IDIBELL (Bellvitge Biomedical Research Institute), from Hospital de Bellvitge; VHIR (Vall d Hebron Research Institute), related with Hospital Vall d Hebron; and IGTP (Health Sciences Research Institute of the Germans Trias i Pujol Foundation), from Hospital Germans Trias I Pujol, all of them placed in Barcelona area, were the first four accredited institutes in Spain in The objective of ISCIII initiative is to promote hospitals as research centers, providing the necessary equipment to create healthcare and teaching environments and high-quality research. Amsterdam BioMed OBN - Oxford One Nucleus Cambridge/London BioWin - Belgium GIP Genopole - Paris BioValley - Alsace Lyonbiopole Biocat - BioRegion of Catalonia BioPMed - Torino Stockholm Science City Medicon Valley Denmark/Sweden BioTOP Berlin-Bradenburg BioM - Munich LISA - Vienna These institutes are a key piece of the Catalan research system that reinforces the region s capacities on translational research. Catalonia Life Sciences Report

14 Executive Summary Major infrastructures From 2005 to 2011, three major scientific infrastructures have been established in Catalonia, thanks to political and economic regional efforts. All of them are reference centers no only in Spain, but at European level. The Alba Synchrotron is operative since There are 49 synchrotrons in the world and Alba is the first installation of its kind in Spain. 201 million euros have been invested in this project since 2003, financed fifty-fifty by the Catalan and Spanish Governments. The Alba Synchrotron can have up to 33 beamlines and receive more than 1,000 researchers every year. The National Centre for Genomic Analysis (CNAG) was created in 2009 with the support of the Spanish and Catalan Governments and started operating in March CNAG s purpose is to carry out large scale DNA sequencing projects. The centre is located within Barcelona Science Park and on 1,200 square meters. Its sequencing power is one of the largest in Europe. The Barcelona Supercomputing Center (BSC), Spain s National Supercomputing Center, plays host to the Mare Nostrum supercomputer, one of the most powerful in Europe. BSC provides High Performance Computing (HPC) services for Spanish researchers and is a member of PRACE (Partnership for Advanced Computing in Europe), a joint initiative of 24 countries that allows to offer pan- European HPC services to academia and industry. Campuses of excellence Campus of excellence is an initiative of the former Spanish Ministry of Education to foster research, technology transfer and innovation around university campuses, and acknowledges joint private-public efforts to achieve these goals. Catalonia has six campuses of excellence. CoE promote strategic links and interactions between research centers, science & technology parks, production environments and other players, in order to develop ecosystems that link education, knowledge, research and innovation. The six Catalan campuses of excellence received 41 million euros out of 182 invested by Spanish Government in this initiative in 2009 and The six existing Catalan campuses are: BKC - Barcelona Knowledge Campus of Universitat de Barcelona (UB) and Universitat Politècnica de Catalunya (UPC) UAB CEI: Promoting knowledge, encouraging innovation of Universitat Autònoma de Barcelona (UAB) UPC Energy Campus Energy for Excellence of Universitat Politècnica de Catalunya (UPC) HUBc - Health Universitat de Barcelona Campus of Universitat de Barcelona (UB) Icaria CEI of Universitat Pompeu Fabra (UPF) CEICS - Campus of International Excellence Southern Catalonia of Universitat Rovira i Virgili (URV) 14 Catalonia Life Sciences Report 2011

15 Focus on Catalonia Life Sciences Companies The Catalan business network has a significant number of start-ups, SMEs and consolidated pharma companies. Innovation and internationalization are at the core of their business strategy, being biomedicine the main field of activity. Additionally, Catalan biotech companies are responsible for 85% of registered patents. Despite global crisis and investment difficulties, Catalonia continues to be the Spanish leader in innovation related to the set-up of new biotechnology companies. 11 biotechnology companies were created in Catalonia only in 2010, representing 23% of all the new companies established in Spain. Most Catalan biotechnology companies have been created after 2000, which accounts for the big boom seen during the first decade of the 21st century. The establishment of incubators and science parks, along with government grants to helps creation of companies (CIDEM- ACC1Ó), have contributed to this growth. Figure 3.4 Establishment year of the BioRegion companies The increase in new biotech companies in Catalonia has remained constant during the last years, with about new firms per year (figure 3.4).The figures of 2011 (12 new companies) show that entrepreneurs in Catalonia continue to be active despite the economic crisis and the difficult context. 77.4% of new companies in the BioRegion arise from private initiatives, either as start-ups from another company or as a particular entrepreneur action. However, if we only consider companies engaged in research and exclude service or support companies, the weight of public initiative in the set-up of company increases significantly (figure 3.5). 84.1% of the companies are of Catalan origin while 15.9% are subsidiaries of international companies (figure 3.6). It should be highlighted that 58% of the companies in the BioRegion undertake R&D activities while the rest are services providers. Most of the figures in the following sections distinguish the performance of R&D companies from the rest. Figure 3.5 Origin of the company according to the driving entity R&D Companies 19.1% All Companies 1.7% 5% 5.8% 1% 4.3% 3.4% 13.9% Company University Research center Hospital Others 68.6% 77.4% 18 Number of companies R&D companies Establishment year All companies New companies that did not participate in the survey Figure 3.6 Total number of Catalan origin companies 15.9% Companies created in Catalonia Subsidiary companies 84.1% Catalonia Life Sciences Report

16 Catalan Life Sciences industry employs 22,000 people, half of which work on R&D activities Activity environment Barcelona and its metropolitan area concentrate 85% of life sciences companies located in Catalonia. However, as shown in figure 3.7, there are research companies all over the BioRegion. 81% of the companies have a single work center and they choose to set up mainly in an industrial environment industrial parks or technology centers, where 44% of the companies are located and in urban areas (34%), followed by science and technology parks (29%). Most of R&D start-ups are located in knowledge-driven environments: up to 38.8% in science and technology parks and 17% in universities and hospitals. Chapter 5 of this report highlights the importance of parks as a meeting point for research and business and its role in the creation and consolidation of the BioRegion. Figure 3.7 Geographic distribution of the companies in the BioRegion Red biotech White biotech Green biotech Medical technologies Ripoll Manlleu Bigues i Riells Palau Solità i Plegamans Sentmenat Lliça d Amunt Girona Alpicat Masquefa Sant Feliu de Llobregat Abrera Cervera Rubí Santpedor Bellaterra Sabadel Terrassa Sant Quintí de Mediona Sant Just Desvern Barberà del Vallès Les Franqueses del Vallès Llinars del Vallès Sant Pol de Mar Granollers Parets del Vallès Mollet del Vallès Constantí Valls Villanova i la Geltrú Gavà El Masnou Santa Perpètua de la Mogoda Amposta Castellvell del Camp Reus Tarragona Castelldefels Sant Joan Despí Sant Boi de Llobregat Hospitalet de Llobregat Ripollet Badalona Montcada i Reixat Cornellà de Llobregat Esplugues de Llobregat Cerdanyola del Vallès Sant Cugat del Vallès Barcelona 16 Catalonia Life Sciences Report 2011

17 Figure 3.8 Main activities of the BioRegion companies Number of companies R&D+i Production Marketing / Sales Services 0 Scie-Tech consultancy CRO Equipment suppliers Training Business development CMO Quality & regulatory Industrial property Financing/investors Main activities Figure 3.9 BioRegion companies business model 25.5% 6.7% Dual model company Product company Technology company N/A 31.3% 36.5% Business model Nearly half of companies (48.8%) have activities along two or three different phases of the value chain. This is a highly technological and focused industry, with great added value: 58.2% of the companies are engaged in R&D activities and 40.3% in manufacturing. Only 18.2% of R&D companies carry out activities throughout the whole value chain, from discovery to market. 50% of the companies conduct marketing and sales activities and most of them (61.5%) choose to use their own marketing channels, whereas 46.2% sign distribution agreements. Many companies, though, combine both marketing options, depending on the product or the market. The percentage of service companies has significantly increased, whether they render those services as a core activity or to supplement their R&D activities. This increase is partly due to the fact that the market has grown as a result of the outsourcing trend. The different activities of service companies are detailed in figure 3.8. The companies in the BioRegion choose mainly a dual business model, which combines own product development and services offered to third parties (figure 3.9). This dual model stands as the best option, as the search for liquidity becomes a priority for the companies in a difficult financial environment. Catalonia Life Sciences Report

18 Activity fields Biomedicine is the main area of activity of the Bioregion companies. As shown in figure 3.10, 47.1% of firms work in red biotech (58.7% of R&D companies) and 52.4% work in medical technologies (45.5% of R&D segment). The figures are smaller for green and white biotech, even though 2010 Biocat s survey showed higher companies performance in these subsectors compared to % of all companies work in green biotech (28.1% of R&D companies) while they were only 16.7% in On the other hand, 47% of R&D companies work in white biotech, but this subsector occupies only 27.4% of the whole business network, with very few service companies working in this field. In any case, the figure has increased substantially since 2009 when white biotech occupied 17.6% of companies in the BioRegion. Regarding application areas (figure 3.11) it is interesting to highlight that 18% of all companies are engaged in cosmetics, that is a significant activity for small pharma companies, especially in the OTC and dermopharmacy lines. Most companies, especially those engaged in offering services and advisory activities, are working in different application areas of diverse subsectors of activity. Only 31% of companies focus on a single application area. Figure 3.10 Subsectors of activity of the BioRegion companies Green biotech R&D companies All companies White biotech Medtech Red biotech 0% 50% 100% 18 Catalonia Life Sciences Report 2011

19 1. Biomedicine Human health accounts for 73.3% of the activity of companies engaged in biomedicine, whereas 16.7% of them focus on animal health. These percentages remain quite the same when talking about R&D companies: 76% work on human health and 19.8% on animal health. Human health predominance in the Catalan biotech industry is due to interaction of several factors: an excellent network of hospital research institutes, which carry out outstanding translational research; public investments in recent years in these fields; and business and research activities of several pharma companies with notable weight in the industry. Even so, the biomedicine subsector focused on animal health offers great potential to Catalonia. A good example of this is that in 2011 Pfizer moved to Catalonia a substantial part of its animal health research activities to a plant located in Olot (Girona). Business efforts put into biomedical research are mainly aimed at developing new therapeutic and biological products (66.3%), medical devices (46.3%), in vitro diagnostic (32.6%) and, to a lesser degree, electromedicine (e-health) and diagnostic imaging (14.7% each), as shown in figure Main therapeutic areas of R&D companies are central nervous system (CNS) and oncology (ranging close to 27%), followed by cardiovascular diseases, immunology and dermatology (close to 19%) and infectious diseases (16.5%) mainly done by start-ups which could cover a niche often discarded by big corporations. Some differences were recorded when comparing R&D to commercialization activities. In this latter, cardiovascular, oncology and dermatology continue to be leading areas, whereas CNS decreases to 13%. (figure 3.12). Figure 3.11 Application areas in subsectors of activity 70% Biomedicine Percentage of Companies 60% 50% 40% 30% 20% 10% Green biotech White biotech Others 0% Pharma or biological therapies Medical devices In vitro diagnostic Electromedicine Diagnostic imaging R&D companies All companies Nutrition Environment Agricultural R&D companies All companies Bioprocesses Biomaterials Fine chemical R&D companies All companies Biotreatments Cosmetics Bioinformatics Areas of activity R&D companies All companies Catalonia Life Sciences Report

20 Figure 3.12 Therapeutic areas in research and commercialization of the BioRegion companies R&D Companies 35 Number of Companies R&D Commercialization 5 0 Central Nervous System Oncology Cardiovascular System Immunology Dermatology Infectious diseases Inflammatory diseases Gastrointestinal System Respiratory System Obstetrics and Gynecology Ophthalmology Trauma and locomotor system Hematology Genitourinary System Endocrinology Others Therapeutic areas All Companies 35 Commercialization 30 Number of Companies Central Nervous System Oncology Cardiovascular System Immunology Dermatology Infectious diseases Inflammatory diseases Gastrointestinal System Respiratory System Obstetrics and Gynecology Ophthalmology Therapeutic areas Trauma and locomotor system Hematology Genitourinary System Endocrinology Others 20 Catalonia Life Sciences Report 2011